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Objectives The objective of this study is to investigate the incidence and clinical implications of
thrombus on baseline angiography among patients presenting with non–ST-segment elevation
acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI).
Background Given current advances in the pharmacological and mechanical treatment of ACS pa-
tients managed with an early invasive strategy, the incidence and prognostic importance of pre-
procedural lesion thrombus is warranted.
Methods In the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial, a total
of 3,627 patients with moderate- and high-risk ACS undergoing PCI had their baseline and ﬁnal
post-PCI angiograms analyzed by an independent angiographic core laboratory.
Results Patients with thrombus (n  530 [15%]) compared with those without thrombus had
higher rates of impaired ﬁnal epicardial coronary ﬂow (ﬁnal Thrombolysis In Myocardial Infarction
[TIMI] ﬂow grade 3: 89.6% vs. 97.1%, p  0.0001). Thrombus was an independent predictor of 30
day death (odds ratio [OR]: 3.16 [95% conﬁdence interval (CI): 1.20 to 8.37], p  0.02), and myocar-
dial infarction (MI) at 30 days (OR: 1.62 [95% CI: 1.17 to 2.24], p  0.003) and at 1 year (OR: 1.56
[95% CI: 1.16 to 2.08], p  0.003). Patients with thrombus had signiﬁcantly higher rates of stent
thrombosis (ST) compared with patients without thrombus at 30 days (2.8% vs. 1.1%, p  0.002)
and at 1 year (3.7% vs. 1.8%, p  0.003), and thrombus was an independent predictor of ST at both
30 days (OR: 2.61 [95% CI: 1.38 to 4.91]) and 1 year (OR: 2.98 [95% CI: 1.64 to 5.42]).
Conclusions Pre-procedural thrombus was present in 15% of moderate- and high-risk ACS patients
undergoing PCI in the ACUITY trial. Baseline thrombus predicts increased ischemic complications at
30 days including a 3-fold increased risk of death as well as MI up to 1 year. Further evaluation of
adjunctive pharmacotherapy is needed in this high-risk population. (J Am Coll Cardiol Intv 2011;4:
769–77) © 2011 by the American College of Cardiology Foundation
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770Pre-procedural thrombus is a harbinger of procedural
complications following primary percutaneous coronary
intervention (PCI) for ST-segment elevation myocardial
infarction (MI) (1–3). Thrombus can lead to poor out-
comes by various mechanisms including distal emboliza-
tion, impaired myocardial perfusion, increased myocar-
dial necrosis and decreased left ventricular function (4,5),
with subsequent reduced survival benefit at follow-up
(6 – 8). The purpose of this study is to determine the
incidence, predictors and prognosis of pre-procedural throm-
bus among moderate- and high-risk acute coronary syn-
dromes (ACS) patients undergoing contemporary guideline-
recommended PCI in the ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) trial (9–12).
Methods
Study population and design.
The design and results of the
ACUITY trial have been previously
published (12,13). Briefly, 13,819
patients with moderate- and high-
risk ACS were randomized in an
open-label fashion to 1 of 3 anti-
thrombotic regimens: heparin (un-
fractionated or enoxaparin at site
discretion) plus a glycoprotein IIb/
IIIa inhibitor (GPI), bivalirudin
plus a GPI, or bivalirudin mono-
therapy. Patients assigned to hepa-
rin plus a GPI or bivalirudin plus a
GPI were randomly assigned again
in a 2-by-2 factorial design to either
upstream or deferred initiation. In
patients assigned to bivalirudin
monotherapy, GPI administration
was reserved for “bail-out” use for
procedural PCI complications or
suboptimal results.
Coronary angiography was required per protocol within
72 h of randomization, with subsequent triage to treatment
with PCI, coronary artery bypass grafting (CABG), or
medical management at the physician’s discretion. The
study was approved by the institutional review board or
equity interests in Medtronic and Savacor; has received research grants from Daiichi
Sankyo, Eli Lilly & Co., and Maquet; has received lecture fees from Schering-Plough,
Bristol-Myers Squibb, and Datascope; received grant support from The Medicines
Company, Schering-Plough, Bristol-Myers Squibb, sanofi-aventis, Millennium Phar-
maceuticals, Eli Lilly & Co., and Daiichi Sankyo; and is on the Speakers’ Bureau for
CV Therapeutics and The Medicines Company. Dr. White has received grant
support from The Medicines Company, sanofi-aventis, Schering-Plough, Eli Lilly &
Co., Merck Sharp & Dohme, National Institutes of Health, Pfizer, Roche, Johnson
& Johnson, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, Pharma Development,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
GPI  glycoprotein IIb/IIIa
inhibitor
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
RR  relative risk
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarctionand Bristol-Myers Squibb, and is a consultant to Regado Biosciences. Dr. Mehran is
M
2ethics committee at each participating center, and all pa-
tients signed written informed consent.
Angiographic analysis. Comprehensive quantitative coro-
ary angiography of baseline and final angiograms from
,921 consecutive patients from the U.S. centers was per-
ormed by an independent angiographic core laboratory. All
ngiograms were evaluated by reviewers blinded to treat-
ent assignment using validated quantitative methods
Medis, Leiden, the Netherlands). Complete baseline and
ost-procedural angiographic data were available in 3,627
atients undergoing PCI. Coronary thrombus was defined
s an intraluminal filling defect or an area of contrast
taining noted within the target stenosis. Thrombus burden
as assessed as the total area based on the diameter and
ength of the observed angiographic thrombus. Abrupt
losure was defined as a decrease in Thrombolysis In
yocardial Infarction (TIMI) flow to grade 0 or 1 with
ecurrent stenosis similar to or worse than that present
efore PCI. No-reflow was defined as reduced antegrade
ow (TIMI flow grade 2) in the absence of occlusion at
he treatment site or evidence of distal embolization. Distal
mbolization was defined as the migration of a filling defect
o distally occlude the infarct-related vessel or 1 of its
ranches, or a new abrupt cutoff of the distal vessel or its
ranch. Other variables included baseline TIMI flow grade
nd myocardial blush score assessed on a scale of 0 to 3
sing methods previously described (14,15). The extent of
oronary artery disease (CAD) was quantified by an angio-
raphic surrogate of disease burden (the total length in
illimeters of all lesions with a 30% diameter stenosis in
major epicardial vessel), and the Duke Jeopardy Score
stimating the amount of myocardium at risk on the basis of
he particular location of coronary artery stenosis, in which
higher score corresponds to a greater area of jeopardized
yocardium (16).
Deﬁnitions and statistical analyses. The endpoints of this
nalysis included: 1) composite ischemia (defined as death
rom any cause, MI, or unplanned revascularization for
schemia); 2) definite or probable stent thrombosis (ST) at
0 days and at 1 year; and 3) non-CABG–related major
leeding; and 4) net adverse clinical event (composite
schemia or non-CABG–related major bleeding) at 30 days.
he definitions of clinical endpoints have been previously
escribed (13). ST was classified according to the Academic
consultant to and on the advisory board for Abbott Vascular, AstraZeneca, OrthoMc-
eil, Regado Biosciences, and received research grants (institutional) from Bristol-
yers Squibb/sanofi-aventis. Dr. Hamon has received research grants from Eli Lilly
Co., GlaxoSmithKline, and The Medicines Company. Dr. Stone reports being on the
dvisory board for and receiving honoraria from Boston Scientific and Abbott Vascular, and is
consultant to Medtronic, Merck, The Medicines Company, Eli Lilly & Co., AstraZeneca,
nd Bristol-Myers Squibb-Sanofi. All other authors have reported that they have no
elationships to disclose.anuscript received November 11, 2010; revised manuscript received January 10,
011, accepted February 4, 2011.
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771Research Consortium criteria (17). We compared baseline
characteristics and outcomes according to the presence of
thrombus and assessed the independent impact of thrombus
on 30-day and 1-year outcomes. Furthermore, we evaluated
the effect of antithrombin therapy on composite ischemia or
non-CABG–related bleeding in patients with thrombus.
All endpoints were adjudicated by a clinical events commit-
tee blinded to the treatment assignment.
Continuous variables were compared using the Kruskal-
Wallis test. Categorical values were compared by the chi-
square or Fisher’s exact test. For comparison of cumulative
30-day and 1-year outcomes between the 2 groups, we used
Kaplan-Meier survival analysis and the log-rank test. Cox
proportional hazard regression analysis was performed to
determine the predictors of: 1) pre-procedural thrombus;
and 2) individual components of composite ischemia, major
bleeding, and ST. The following variables considered for
the pre-procedural thrombus model included: age (per
10-year increment), sex, diabetes, insulin-treated diabetes,
hypertension, hyperlipidemia, current smoking, previous
MI, previous PCI, previous CABG, chronic renal insuffi-
ciency, baseline anemia, planned GPI use (bivalirudin or
heparin plus a GPI) versus planned non-GPI use (bivaliru-
din monotherapy), aspirin or thienopyridine on admission
or pre-procedure, duration from first study drug to angio-
gram, number of diseased vessels, extent of CAD (per
10-mm increment of lesions 30%), right CAD versus
non–right CAD, reference vessel diameter, proximal lesion.
Variable for the components of composite ischemia, major
bleeding, and ST included: thrombus, age (per 10-year
increment), sex, diabetes, insulin-treated diabetes, hyper-
tension, hyperlipidemia, current smoking, previous MI,
previous PCI, previous CABG, renal insufficiency, baseline
anemia, baseline white blood cell count (per 1,000 increase),
left ventricular ejection fraction (per 10% increase), bio-
marker elevation, ST-segment deviation, bivalirudin plus a
GPI (vs. heparin plus a GPI), bivalirudin alone (vs. heparin
plus a GPI), extent of CAD, number of diseased vessels, left
anterior descending artery disease, proximal lesion, baseline
TIMI flow grade, baseline blush score, eccentricity, ulcer-
ation, aneurysm, moderate-to-severe calcification, presence
or absence of collaterals, worst percent diameter stenosis,
stent type (drug-eluting stent [DES] vs. bare-metal stent
[BMS]), use of 2 stents, aspiration device use, distal
protection device use, aspirin at discharge, and thienopyri-
dine at discharge.
To evaluate the relation between thrombus burden and
ST, patients with measurable thrombus area (n  432,
1.5%) were divided into tertiles of thrombus area (17
m2, n  156; 17 to 32 mm2, n  135; and 32 mm2,
 141). All analyses were based on intention to treat. The
values, odds ratios (OR), and corresponding 2-sided 95%onfidence intervals (CI) for predictors are presented.esults
Baseline characteristics. Pre-procedural thrombus was pres-
ent in 530 (15%) patients. Patients with thrombus were
younger, were more frequently male, had lower prevalence of
comorbidities including diabetes, hypertension, hyperlipid-
emia, and chronic renal insufficiency, and had less previous MI
and PCI (Table 1). Current smoking, baseline troponin ele-
vation, and ST-segment deviation was more common in
patients with thrombus.
Study drug and procedural characteristics. The bail-out use
f GPI in the bivalirudin monotherapy group was more
requent in patients with thrombus versus without thrombus
17.3% vs. 6.5%, p  0.0001) (Table 2). BMS use was
ignificantly higher in patients with thrombus than those
ithout thrombus. Although thrombus aspiration or distal
rotection device were used more frequently in patients with
hrombus, overall usage was low. Among patients with
hrombus, those treated with versus without thrombus aspira-
ion had similar rates of composite ischemia at 30 days (14.1%
s. 12.9%, p 0.81) and at 1 year (22.7% vs. 21.8%, p 0.72).
edication use after discharge was similar between the 2
roups, except for greater use of beta-blockers in the thrombus
roup (83.4% vs. 77.3%, p  0.002).
Baseline and ﬁnal angiographic characteristics. Left ventric-
lar ejection fraction was lower in patients with thrombus than
Table 1. Baseline Clinical Characteristics
Thrombus ()
(n  530)
Thrombus ()
(n  3,097) p Value
Age, yrs 60 [52–69] 61 [53–71] 0.03
Male 73.6 69.0 0.04
Weight, kg 88 [77–100] 87 [75–100] 0.14
Diabetes 26.1 33.0 0.002
Insulin-treated diabetes 7.6 9.6 0.15
Hypertension 61.5 71.7 0.0001
Hyperlipidemia 49.5 64.2 0.0001
Current smoker 40.2 30.0 0.0001
Previous MI 30.5 35.3 0.03
Previous PCI 31.6 50.9 0.0001
Previous CABG 19.7 22.4 0.17
Renal insufﬁciency* 13.5 17.6 0.02
Baseline cardiac biomarker
elevation or ST-segment
deviation
86.6 62.9 0.0001
Baseline troponin elevation 79.8 52.4 0.0001
ST-segment deviation 1 mm 30.0 25.1 0.02
TIMI risk score
0–2 16.1 12.4 0.04
3–4 56.5 55.7 0.80
5–7 27.5 31.8 0.07
Values are median [interquartile range] or %. *Renal insufficiency was defined as calculated
creatinine clearance60 ml/min by the Cockcroft-Gault equation.
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneouscoronary intervention; TIMI Thrombolysis In Myocardial Infarction.
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772those without thrombus (Table 3). Patients with thrombus had
more frequent right coronary artery target lesions, proximal
coronary location, larger vessels, and more severe diameter
stenosis compared with patients without thrombus. Patients
with thrombotic lesions had more TIMI flow grade 0/1 at
baseline and had lower rates of TIMI flow grade 3 and
myocardial blush grade 3 after final intervention despite having
better acute luminal results with larger minimum lumen
diameter than patients without thrombus. Procedural compli-
cations such as spasm, abrupt closure, distal embolism, or
no-reflow were all more frequent in patients with thrombus
(Table 3).
Predictor of pre-procedural thrombus formation. After ad-
usting demographic, treatment, and angiographic covariates,
redictors of pre-procedural thrombus formation included
aseline reference diameter (OR: 1.67 [95% CI: 1.40 to 1.98],
 0.0001), Jeopardy Score (OR: 1.14 [95% CI: 1.09 to 1.18],
 0.0001), current smoking (OR: 1.31 [95% CI: 1.07 to
.60], p 0.01), and right CAD (OR: 1.43 [95% CI: 1.09 to
.88], p  0.01). By contrast, the following factors were
Table 2. Drug and Procedural Characteristics
Thrombus ()
(n  530)
Thrombus ()
(n  3,097) p Value
Antithrombin assignment
Heparin (UFH or LMWH) plus a GPI 30.8 32.8 0.37
Upstream GPI use 16.8 15.9 0.61
Deferred GPI use 14.0 16.9 0.10
Bivalirudin plus a GPI 32.1 34.6 0.28
Upstream GPI use 19.1 17.5 0.39
Deferred GPI use 13.0 17.1 0.02
Bivalirudin monotherapy 37.2 32.6 0.04
Bail-out use of GPI 17.3 6.5 0.0001
Duration from ﬁrst study drug to
angiography, h
2.8 [0.9–12.5] 2.9 [0.9–13.5] 0.51
Duration from ﬁrst study drug to
PCI, h
3.4 [1.3–13.8] 3.4 [1.3–15.0] 0.67
PCI procedure
Stent use 93.8 93.7 0.99
DES 81.5 85.1 0.04
BMS 20.4 14.6 0.0009
Both 8.1 6.0 0.07
Thrombus aspiration 9.4 1.2 0.0001
Distal protection devices 4.2 1.7 0.0007
Medications after discharge
Aspirin 97.0 97.0 1.00
Thienopyridines 94.9 94.0 0.18
Statins 85.0 83.2 0.33
Beta-blocker 83.4 77.3 0.002
ACE inhibitor 57.5 56.6 0.73
Values are median [interquartile range] or %.
ACE  angiotensin-converting enzyme; BMS  bare-metal stent(s); DES  drug-eluting
stent(s); GPI  glycoprotein IIb/IIIa inhibitor; LMWH  low molecular-weight heparin; UFH 
unfractionated heparin; other abbreviations as in Table 1.rotective of pre-procedural thrombus formation: previousCI (OR: 0.60 [95% CI: 0.47 to 0.75], p  0.0001),
yperlipidemia (OR: 0.74 [95% CI: 0.60 to 0.92], p 0.006),
riple-vessel disease (OR: 0.74 [95% CI: 0.59 to 0.93],
 0.01), planned GPI use (OR: 0.80 [95% CI: 0.65 to
.98], p  0.03), and thienopyridines on admission (OR:
.77 [95% CI: 0.59 to 0.99], p  0.04).
Table 3. Baseline and Final Angiographic Characteristics
Thrombus ()
(n  530)
Thrombus ()
(n  3,097) p Value
Left ventricular ejection fraction, % 62 [55–70] 66 [57–73] 0.0001
Culprit lesion location
LAD 32.2 42.9 0.0001
RCA 46.4 38.0 0.0004
LCX 36.9 36.9 1.00
Number of diseased lesions 4.3 2.7 4.3 2.6 0.57
Number of attempted vessels 1.2 0.4 1.2 0.4 0.19
Proximal lesion 44.0 36.3 0.0001
TIMI ﬂow grade
Baseline
0/1 47.5 17.6 0.0001
2 16.7 13.0 0.03
3 35.8 69.4 0.0001
Final
0/1 5.3 1.2 0.0001
2 5.1 1.7 0.0001
3 89.6 97.1 0.0001
Blush score
Baseline
0/1 49.4 17.8 0.0001
2 13.7 19.4 0.002
3 36.9 62.8 0.0001
Final
0/1 6.6 2.0 0.0001
2 15.0 11.5 0.03
3 78.4 86.7 0.0001
Reference diameter, mm
Baseline 2.9 0.6 2.7 0.6 0.0001
Final 3.0 0.6 2.8 0.6 0.0001
Minimum lumen diameter, mm
Baseline 0.5 0.5 0.8 0.5 0.0001
Final 2.4 0.7 2.3 0.6 0.0009
Diameter stenosis, %
Baseline 83.8 16.4 71.9 15.1 0.0001
Final 19.1 15.8 16.8 10.7 0.0003
Periprocedural complications
Spasm 4.7 2.4 0.003
Abrupt closure 2.8 0.4 0.0001
Distal embolization 4.2 0.2 0.0001
No reﬂow 1.3 0.4 0.01
Perforation 0.2 0.2 1.00
Values are median [interquartile range] %, or mean SD.
LAD left anterior descendingartery; LCX left circumflexartery; RCA right coronary artery;other abbreviations as in Table 1.
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773Association of thrombus with clinical outcomes. At 30 days,
patients with thrombus had a worse net adverse clinical
event (18.3% vs. 14.0%, p 0.006) and composite ischemia
(13.0% vs. 9.4%, p  0.007) with a higher incidence of
death (1.5% vs. 0.7%, p  0.05) and MI (10.6% vs. 7.1%,
p  0.004) versus those without thrombus (Table 4). Un-
planned revascularization and bleeding rate were similar in
the 2 groups at 30 days. At 1 year, composite ischemia was
similar between the 2 groups (21.9% vs. 20.7%, p  0.52);
however, the higher incidence of MI in the thrombus group
persisted at 1 year (14.3% vs. 9.9%, p  0.002) (Table 4). A
landmark analysis (Figs. 1A to 1D) demonstrated that the
higher event rates associated with the presence of thrombus
was due to early events up to 30 days, including higher death
and MI. Conversely, from 30 days to 1 year, composite
ischemia was lower in patients with thrombus, due to a
lower mortality (relative risk [RR]: 0.35 [95% CI: 0.13 to
0.97], p  0.03) and lower rate of unplanned revasculariza-
tion (RR: 0.63 [95% CI: 0.44 to 0.91], p  0.01).
In multivariable analysis, pre-procedural thrombus was an
independent predictor of 30 day death (OR: 3.16 [95% CI:
1.20 to 8.37], p  0.02) and MI (OR: 1.62 [95% CI: 1.17 to
.24], p 0.003) and cumulative MI at 1 year (OR: 1.56 [95%
I: 1.16 to 2.08], p  0.003). However, the presence of
hrombus did not predict ischemic events between 30 days to
year (death: OR: 0.32 [95% CI: 0.10 to 1.04], p 0.06, MI:
R: 1.34 [95% CI: 0.77 to 2.33], p  0.30, or unplanned
evascularization: OR: 0.85 [95% CI: 0.52 to 1.40], p 0.53]).
Association of thrombus with ST. Cumulative ST at 1 year
as higher in patients with thrombus, mainly due to the
igher rates at 30 days (Fig. 1E, Table 4). By multivariable
nalysis, pre-procedural thrombus was an independent pre-
ictor of ST at 30 days (OR: 2.61 [95% CI: 1.38 to 4.92],
Table 4. Clinical Outcomes
Outcomes, %
Thrombus ()
(n  530)
T
(
30 days
Net adverse clinical event 18.3
Composite ischemia 13.0
Death 1.5
MI 10.6
Unplanned revascularization 4.2
Major bleeding 7.2
Stent thrombosis* 2.8
1 year
Composite ischemia 21.9
Death 2.3
MI 14.3
Unplanned revascularization 11.3
Stent thrombosis* 3.7
*Definite/probable stent thrombosis according to Academic ResearchCI confidence interval; MImyocardial infarction; OR odds ratio. 0.003) and cumulatively at 1 year (OR: 2.98 [95% CI:
.64 to 5.42], p  0.0003), but did not predict ST between
0 days to 1 year (OR: 1.38 [95% CI: 0.39 to 4.88], p 
.62). We found no association between thrombus burden
nd ST at 30 days (first tertiles: 1.9% vs. second tertiles:
.7% vs. third tertiles: 2.1%, p  0.58) and at 1 year (3.6%
s. 3.7% vs. 2.9%, p 0.92). Patients with thrombus treated
ith BMS (n  98) versus DES (n  432) had no
ignificant differences in rates of ST at 30 days (1.0% vs.
.3%, p  0.23) and at 1 year (4.1% vs. 2.1%, p  0.36),
lthough the numbers were small.
Effects of antithrombotic regimens on clinical outcomes in
patients with thrombus. Among the 530 patients with
hrombus, antithrombotic treatment allocation included
eparin plus a GPI (n  163), bivalirudin plus a GPI (n 
70), or bivalirudin alone (n  197). Major bleeding at 30
ays was reduced by 60% with bivalirudin alone compared
ith heparin plus a GPI (Table 5). There was no difference
n 30-day and 1-year net adverse clinical events or compos-
te ischemia among antithrombin groups (Table 5). The use
f bail-out GPI in the bivalirudin monotherapy group did
ot affect composite ischemia at 30 days (11.8% vs. 16.6%,
 0.48) or at 1 year (20.7% vs. 19.7%, p  0.90). Among
he 170 patients with thrombus receiving bivalirudin plus a
PI, the assignment to upstream versus deferred GPI
herapy resulted in a significant reduction in 1-year com-
osite ischemia (13.1% vs. 27.4%, p  0.03) and MI (9.0%
s. 21.2%, p  0.03) (Table 6).
iscussion
Thrombotic lesions remain a common finding in patients
with moderate- and high-risk ACS undergoing early an-
us ()
,097) p Value
Adjusted
OR [95% CI]
Adjusted
p Value
.0 0.006 1.29 [0.99–1.70] 0.06
.4 0.007 1.49 [1.10–2.01] 0.009
.7 0.05 3.16 [1.20–8.37] 0.02
.1 0.004 1.62 [1.17–2.24] 0.003
.5 0.42 1.20 [0.75–1.92] 0.45
.1 0.32 1.30 [0.87–1.94] 0.20
.1 0.002 2.61 [1.38–4.92] 0.003
.7 0.52 1.30 [0.98–1.72] 0.07
.0 0.48 0.94 [0.45–1.97] 0.87
.9 0.002 1.56 [1.16–2.08] 0.003
.7 0.10 1.24 [0.87–1.77] 0.23
.8 0.003 2.98 [1.64–5.42] 0.0003
tium (ARC) definitions.hromb
n  3
14
9
0
7
3
6
1
20
3
9
13
1
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; RR 
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774giography and triage to PCI. The presence of thrombus
increases procedural complications, likely explaining the
associated ischemic complications. Baseline lesion thrombus
predicted 30-day mortality, MI, and ST, as well as cumu-
lative MI and ST 1 year following PCI, with more than a
2-fold increased risk of death or ST and 1.5 times risk of MI
at 30 days. Paradoxically, baseline thrombus identifies a
population with lower risk of mortality and need for
Figure 1. Landmark Analyses
Landmark analyses of (A) composite ischemia, (B) death, (C) MI, (D) unplanne
to 1 year in patients with versus without thrombus. MI  myocardial infarctionunplanned revascularization between 30 days to 1 year.Planned GPI and thienopyridine use on admission pre-
dicted less thrombus, but the antithrombotic regimen did
not affect ischemic outcomes of patients with thrombus.
Bivalirudin monotherapy reduced bleeding complications,
and for those patients with thrombus, upstream use of GPI
(vs. deferred GPI) on a background of bivalirudin mono-
therapy reduced 1-year composite ischemia and MI.
Prevalence of thrombus on baseline angiography. Previous
scularization, and (E) deﬁnite or probable ST up to 30 days and from 30 days
relative risk; ST  stent thrombosis.d revastudies have reported an incidence of thrombus ranging from
e
o
b
c
h
o
p
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7757% to 23% in patients with unstable angina (1,18–20), de-
pending on disease acuity, epicardial blood flow, cardiac
marker elevation, and the timing of angiography (1,7,18,21).
Consistent with prior studies, larger vessel diameter, right
CAD, higher Jeopardy Score, and active smoking history
predicted thrombotic lesions (21,22). In addition, the planned
use of GPI (non-bail out) was associated with a 20% lower
frequency of pre-procedural lesion thrombus (OR: 0.80 [95%
CI: 0.65 to 0.98], p  0.03), consistent with findings in the
PRISM-PLUS (Platelet Receptor Inhibition for Ischemic
Syndrome Management in Patients Limited by Unstable Signs
and Symptoms) and CAPTURE trials with prolonged 18 to
Table 5. Clinical Outcomes at 30 Days and at 1 Yea
Heparin (UFH or
LMWH)  GPI
(n  163)
Biva
(
At 30 days, %
Net adverse clinical event 22.2
Composite ischemia 15.4
Death 3.1
Nonfatal MI 10.5
Unplanned revascularization 5.0
Major bleeding 10.5
Stent thrombosis 3.1
At 1 year, %
Composite ischemia, % 27.4
Death 4.4
Nonfatal MI 13.2
Unplanned revascularization 16.2
Stent thrombosis 3.1
†Comparison between heparin (UFH or LMWH)  GPI versus bivali
bivalirudin alone. §Comparison between bivalirudin GPI versus biva
Abbreviations as in Tables 1 and 2.
Table 6. Clinical Outcomes at 30 Days and at 1 Year in Patients With
Thrombus Assigned to Bivalirudin Plus a GPI
Upstream GPI
(n  101)
Deferred GPI
(n  69) p Value
At 30 days, %
Net adverse clinical event 13.9 23.3 0.12
Composite ischemia 6.9 14.5 0.10
Death 0 1.4 0.22
MI 5.9 13.2 0.11
Unplanned revascularization 3.0 2.9 0.98
Major bleeding 6.9 10.3 0.44
Stent thrombosis 2.0 2.9 0.70
At 1 year, %
Composite ischemia 13.1 27.4 0.03
Death 1.0 1.4 0.78
MI 9.0 21.2 0.03
Unplanned revascularization 7.1 10.7 0.47
Stent thrombosis 4.0 4.4 0.91bAbbreviations as in Tables 1 and 2.48 h of GPI  heparin therapy (22,23). Shorter 90-min
infusions of intravenous GPI have also shown benefit in
reducing thrombus (21), and our study shows that the benefits
of planned GPI can be seen with shorter infusions yet, with the
median time from first study drug to PCI in ACUITY being
2.9 h (9,10). Although planned GPI use reduced the occur-
rence of thrombus, there was no significant difference noted in
ischemic outcomes from any of the 3 antithrombotic regimens
tested (24).
Treatment and procedural results. Consistent with previous
studies, procedural failure and complications, including abrupt
closure, distal embolism, reduced epicardial and myocardial
perfusions, and slow flow remained higher in patients with
thrombus even after the introduction of a stent or GPI (1,7),
and likely contribute to the increased 30-day ischemic compli-
cations (25) and mortality (21,22,26–28). The landmark anal-
ysis demonstrated that the negative clinical impact of throm-
botic lesions appears to be limited to the first 30 days, during
which patients with thrombus had significantly higher com-
posite ischemia following PCI, with a 3-fold increase in
mortality and a 1.5-fold increase in MI rate. Additional
pharmacological interventions and/or mechanical devices
should be studied to prevent or treat intracoronary thrombus.
Pre-procedural thrombus and clinical outcome. The pres-
nce of baseline thrombus worsens the clinical presentation
f patients with more frequent troponin elevation (1,18),
ut paradoxically, was comprised of a lower-risk population
haracterized by younger age, less diabetes, hypertension,
yperlipidemia, renal insufficiency, and history of prior MI
r PCI than patients without thrombus, which likely ex-
lains the lower event rate seen in the landmark analysis
tients With Thrombus
 GPI
70)
Bivalirudin
Monotherapy
(n  197)
p
Value
p
Value†
p
Value‡
15.7 0.34 0.12 0.60
13.7 0.16 0.69 0.29
1.0 0.09 0.15 0.66
12.2 0.62 0.61 0.30
4.6 0.36 0.86 0.43
3.6 0.51 0.009 0.05
3.1 0.69 0.97 0.69
19.9 0.14 0.23 0.77
1.5 0.08 0.10 0.78
15.5 0.94 0.56 0.63
9.7 0.12 0.21 0.75
3.8 0.64 0.82 0.78
GPI. ‡Comparison between heparin (UFH or LMWH)  GPI versus
alone.r in Pa
lirudin
n  1
17.7
10.0
0.6
8.9
3.0
8.3
2.4
18.9
1.2
14.0
8.7
4.2
rudin 
lirudinetween 30 days and 1 year. Nevertheless, after adjusting for
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776all differences in demographics, angiographic characteristics,
and PCI procedures, thrombus remained independently
predictive of mortality, MI, and ST at 30 days as well as
cumulative rates of MI and ST at 1 year.
The presence of thrombus has been clearly identified as a
factor predisposing to ST (23,29), and in ACUITY, we
show a more than 2-fold increase in acute and subacute ST
despite contemporary PCI, optimal GPI, and antiplatelet
therapy, but no relationship with thrombus burden in
contrast to a prior report (7). Beyond 30 days, there was no
apparent added risk of late ST as a result of the initial
thrombotic lesion. The absence of persistent risk beyond 30
days would suggest that this population is not at long-term
systemic thrombotic risk but rather subject to an acute
thrombogenic mechanism likely localized to a ruptured
plaque. Considering the significant early ischemic risk,
patients with thrombotic lesions on initial angiography may
well benefit from optimal antiplatelet pre-loading and may
justify the use of more potent thienopyridines (30).
Effects of antithrombotic treatments on outcomes in patients
with thrombus. The selection of the antithrombotic regimen
(heparin plus a GPI vs. bivalirudin plus a GPI vs. bivalirudin
monotherapy) did not impact subsequent ischemic events
among patients with thrombus. Although bivalirudin mono-
therapy reduced bleeding complications, the planned upstream
use of GPI did appear to have a role in reducing both the
frequency of thrombus formation, as well as ischemic compli-
cations in thrombotic patients. These benefits were offset by
higher bleeding consequences at the systemic GPI doses tested.
Whether localized intracoronary dosing of GPI may afford
ischemic benefit for thrombotic patients without raising the
bleeding risk remains to be evaluated.
Study limitations. This study is a retrospective analysis, and is
therefore hypothesis generating. The study results only apply to
the specific population evaluated. The incidence of thrombus
in the study is likely underestimated due to the imperfect
sensitivity of angiography in detecting thrombus (2), and
thrombus burden modification related to pre-procedural phar-
macotherapy cannot be excluded (18). Further, the evaluation
of antithrombotic regime on clinical outcomes is a subset
analysis of this subgroup and is entirely hypothesis generating,
but provides insight into possible pharmacological alternatives
to prevent or treat intra-coronary thrombus.
Conclusions
Pre-procedural thrombus remains common (15%) among
moderate- and high-risk ACS patients undergoing contem-
porary PCI. Baseline thrombus predicted 30-day ischemic
complications, including a 3-fold increased mortality risk.
Beyond 30 days, ischemic and mortality complications were
reduced, suggesting absence of persistent thrombotic risk.
Further evaluation of adjunctive pharmacology is needed to
reduce ischemic complications in this high-risk population.Reprint requests and correspondence: Dr. Alexandra J. Lansky,
Yale University School of Medicine, 300 George Street, Suite 759,
New Haven, Connecticut 10022. E-mail: alexandra.lansky@
yale.edu.
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